A detailed history of Bank Of America Corp transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 1,163,424 shares of ESPR stock, worth $2.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,163,424
Previous 4,545,260 74.4%
Holding current value
$2.57 Million
Previous $12.2 Million 78.8%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.84 - $3.24 $6.22 Million - $11 Million
-3,381,836 Reduced 74.4%
1,163,424 $2.58 Million
Q1 2024

May 15, 2024

BUY
$2.02 - $3.02 $8.82 Million - $13.2 Million
4,368,724 Added 2474.69%
4,545,260 $12.2 Million
Q4 2023

Feb 14, 2024

SELL
$0.73 - $3.08 $5,537 - $23,361
-7,585 Reduced 4.12%
176,536 $527,000
Q2 2023

Aug 14, 2023

SELL
$1.2 - $1.76 $394,893 - $579,177
-329,078 Reduced 64.12%
184,121 $255,000
Q1 2023

May 12, 2023

BUY
$1.46 - $7.3 $621,527 - $3.11 Million
425,704 Added 486.55%
513,199 $815,000
Q4 2022

Feb 10, 2023

BUY
$5.09 - $8.5 $110,600 - $184,696
21,729 Added 33.04%
87,495 $545,000
Q3 2022

Nov 14, 2022

SELL
$5.45 - $8.13 $48,101 - $71,755
-8,826 Reduced 11.83%
65,766 $440,000
Q2 2022

Aug 12, 2022

SELL
$4.77 - $6.67 $65,926 - $92,186
-13,821 Reduced 15.63%
74,592 $474,000
Q1 2022

May 16, 2022

SELL
$3.34 - $5.56 $168,135 - $279,890
-50,340 Reduced 36.28%
88,413 $410,000
Q4 2021

Feb 08, 2022

BUY
$4.81 - $11.92 $296,320 - $734,331
61,605 Added 79.85%
138,753 $694,000
Q3 2021

Nov 15, 2021

BUY
$11.34 - $21.37 $578,566 - $1.09 Million
51,020 Added 195.27%
77,148 $929,000
Q2 2021

Sep 13, 2021

BUY
$19.4 - $28.71 $506,883 - $750,134
26,128 New
26,128 $553,000

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $147M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.